Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
By
MaysonL
A good honest bake. Not flashy, but you'll finish the whole bagel.
Summary
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy. The experimental treatment shows a 49% risk reduction in recurrence or death compared to Keytruda alone, building on earlier 2-year data that showed a 44% risk reduction. The vaccine is custom-made for each patient's unique cancer, representing a significant advancement in personalized cancer immunotherapy.
Key quotes
· 4 pulledAt the two-year follow-up, 24 of the 107 (22 percent) who got the experimental vaccine and Keytruda had recurrence or death, while 20 of 50 (40 percent) treated with just Keytruda had recurrence or death, indicating a 44 percent risk reduction.
The companies did not report the breakdown of the two groups in the press release this week for the five-year follow-up, but said the risk reduction was 49 percent.
The vaccines are tailor-made to target each patient's unique cancer.
Previous data from the trial reported that 107 participants received the mRNA vaccine and Keytruda treatment, while the remaining 50 only received Keytruda.
You might also wanna read
Personalized glioblastoma vaccine shows safety and survival promise in phase 1 trial
A phase 1 clinical trial at Siteman Cancer Center found that a personalized vaccine for glioblastoma, an aggressive brain cancer, is safe an
flip.it·9h ago
Triple-action cancer jab amivantamab shrinks tumors in over a third of patients in international trial
An international trial across 11 countries shows that a triple-action cancer injection called amivantamab can shrink or completely eradicate
theguardian.com·1d ago